greeksoup/ stock research
Stock research / United States / Funds / Sarissa Capital Management LP

Sarissa Capital Management LP

CIK 1577524 · latest 13F filed 14 August 2026 · Read the filing on EDGAR

Sarissa Capital Management LP reported 10 US-listed holdings worth $177.9 million in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Innoviva, Inc. (24.1%), Ironwood Pharmaceuticals Inc. (21.7%) and Amarin Corp. PLC ADR (15.0%). Against the quarter before, it opened 1 position, added to 1, trimmed 1 and sold out of 0.

Reported holdings$177.9M+12.8% on Q1 2026
Positions10+1 on Q1 2026
The largest ten100.0%of its reported holdings
Latest 13FQ2 2026filed 14 August 2026
Where the money is
OpenedAdded toHeldTrimmed
INVA24.1%IRWD21.7%AMRN15.0%NBIX11.0%CYTK10.9%LNTH10.4%BHVN4.9%REGN1.5%

The 10 largest of its 10 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.

Reported holdings, quarter by quarter
Q3 2024: $402.3 million in 10 positions$402MQ3 24Q4 2024: $322.9 million in 8 positions$323MQ4 24Q1 2025: $154.7 million in 7 positions$155MQ1 25Q2 2025: $154.4 million in 7 positions$154MQ2 25Q3 2025: $180.4 million in 8 positions$180MQ3 25Q4 2025: $222.9 million in 9 positions$223MQ4 25Q1 2026: $157.6 million in 9 positions$158MQ1 26Q2 2026: $177.9 million in 10 positions$178MQ2 26

What the fund reported holding at each quarter's end; hover a bar for the number of positions

What its reported holdings returned

Held through each quarter, the holdings it reported returned +41.2% over the 7 quarters to 30 June 2026, against +30.2% for the S&P 500.

Its reported holdingsThe S&P 500
80100120140Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Its holdings +41.2%S&P 500 +30.2%

Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.

What it did on the quarter

Opened 1Added 1Held 7Trimmed 1
Opened: 1Added: 1Held: 7Trimmed: 1

Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held

Opened 1

  1. Biogen Inc. BIIB$205,257

Added to 1

  1. Biohaven Ltd BHVN+19,128 shares · +3%

Trimmed 1

  1. Innoviva, Inc. INVA-240,346 shares · -11%

What it holds

CompanySharesValueOf its bookChange in shares
Innoviva, Inc. INVA1.9M$42.9 million24.14%-240.3K
Ironwood Pharmaceuticals Inc. IRWD9.2M$38.7 million21.75%no change
Amarin Corp. PLC ADR AMRN1.7M$26.7 million15.00%no change
Neurocrine Biosciences Inc. NBIX116.5K$19.6 million11.04%no change
Cytokinetics Inc. CYTK228.6K$19.5 million10.95%no change
Lantheus Holdings, Inc. LNTH166.9K$18.5 million10.41%no change
Biohaven Ltd BHVN582.3K$8.7 million4.87%+19.1K
Regeneron Pharmaceuticals, Inc. REGN4.2K$2.6 million1.47%no change
Vor Biopharma Inc. VOR25.4K$467,5960.26%no change
Biogen Inc. BIIB950$205,2570.12%new
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.
Read moreChange is shares against its 13F for the quarter before.